Immunotherapy for hormone receptor‒positive HER2-negative breast cancer by Fatima Cardoso, Kim M. Hirshfield, Kimberly A. Kraynyak, Konstantinos Tryfonidis, Aditya Bardia

Get full text

Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists by Hope S. Rugo, Aditya Bardia, William J. Gradishar, Erika P. Hamilton, Sara A. Hurvitz, Komal Jhaveri, Reshma Mahtani, Sara M. Tolaney

Get full text

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer by Hope S. Rugo, Aditya Bardia, Peter Schmid, Sara M. Tolaney, Anandaroop Dasgupta, Ankita Kaushik, Wendy Verret, Marine Gosset, Adam Brufsky, Javier Cortés, Frederik Marmé

Get full text

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies by Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Laura Spring, Seth A. Wander, Aditya Bardia, Naomi Ko, Beverly Moy, Leif W. Ellisen, Steven J. Isakoff

Get full text

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER) by Laura M. Spring, Lauren Scarpetti, Arielle J. Medford, Andrzej Niemierko, Amy Comander, Therese Mulvey, Lowell Schnipper, Steven J. Isakoff, Beverly Moy, Seth A. Wander, Jennifer Shin, Zanta Ephrem, Anneke R. Laposta, Elyssa Denault, Elizabeth Abraham, Gayle Calistro, Ekaterina Kalashnikova, Angel Rodriguez, Minetta C. Liu, Alexey Aleshin, Jeffrey Peppercorn, Leif W. Ellisen, Aditya Bardia

Get full text

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium anal... by Letizia Pontolillo, Andrew A. Davis, Lorenzo Gerratana, Arielle J. Medford, Judy Wang, Eleonora Nicolo’, Katherine Clifton, Marko Velimirovic, Surbhi Warrior, Emily Podany, Eleni Andreopoulou, Mara Serena Serafini, Laura Munoz-Arcos, Elisabetta Molteni, Marla Lipsyc-Sharf, Caterina Gianni, Nadia Bayou, Charles S. Dai, Diana Giannarelli, Emilio Bria, Cynthia X. Ma, Aditya Bardia, Carolina Reduzzi, Massimo Cristofanilli

Get full text

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context by Maxwell R. Lloyd, Rosario Chica-Parrado, Caroline M. Weipert, Todd C. Knepper, Emily L. Podany, Fabiana Napolitano, Dan Ye, Chang-Ching Lin, Yasuaki Uemoto, Jiemin Liao, Claire Wegrzyn, Christine M. Walko, Lianne Y. Ryan, Jennifer C. Keenan, Arielle J. Medford, Shiyuan A. Liu, Gerburg M. Wulf, Katherine K. Clifton, Cynthia X. Ma, Hyo S. Han, Nicole Zhang, Leif W. Ellisen, Aditya Bardia, Carlos L. Arteaga, Ariella B. Hanker, Seth A. Wander

Get full text